These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 30681655)
21. Fremanezumab for the preventive treatment of migraine. Silberstein SD; Cohen JM; Yeung PP Expert Opin Biol Ther; 2019 Aug; 19(8):763-771. PubMed ID: 31177856 [No Abstract] [Full Text] [Related]
22. Antigens and Antibodies in Disease With Specifics About CGRP Immunology. Taylor FR Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic antibodies against CGRP or its receptor. Bigal ME; Walter S; Rapoport AM Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243 [TBL] [Abstract][Full Text] [Related]
24. Galcanezumab for the prevention of migraine. Frerichs LM; Friedman DI Pain Manag; 2021 Mar; 11(2):101-112. PubMed ID: 33291980 [TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284 [TBL] [Abstract][Full Text] [Related]
26. CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization? Majima M; Ito Y; Hosono K; Amano H Trends Pharmacol Sci; 2019 Jan; 40(1):11-21. PubMed ID: 30502971 [TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Fiedler-Kelly JB; Cohen-Barak O; Morris DN; Ludwig E; Rasamoelisolo M; Shen H; Levi M Br J Clin Pharmacol; 2019 Dec; 85(12):2721-2733. PubMed ID: 31418911 [TBL] [Abstract][Full Text] [Related]
29. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy. Raffaelli B; Reuter U Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis. Soni P; Chawla E Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833 [TBL] [Abstract][Full Text] [Related]
31. CGRP as a new target in prevention and treatment of migraine. Diener HC Lancet Neurol; 2014 Nov; 13(11):1065-1067. PubMed ID: 25297015 [No Abstract] [Full Text] [Related]
32. Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials. Gao B; Lu Q; Wan R; Wang Z; Yang Y; Chen Z; Wang Z Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):819-828. PubMed ID: 33136176 [TBL] [Abstract][Full Text] [Related]
33. Botulinum Toxin in the Treatment of Headache. Becker WJ Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33348571 [TBL] [Abstract][Full Text] [Related]
35. Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine. Med Lett Drugs Ther; 2020 Mar; 62(1593):35-39. PubMed ID: 32555120 [No Abstract] [Full Text] [Related]
36. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Kielbasa W; Helton DL Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684 [TBL] [Abstract][Full Text] [Related]